This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.15% per year. These returns cover a period from January 1, 1988 through June 3, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Is Assertio (ASRT) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Assertio (ASRT) and Shockwave Medical (SWAV) have performed compared to their sector so far this year.
ASRT vs. CTLT: Which Stock Is the Better Value Option?
by Zacks Equity Research
ASRT vs. CTLT: Which Stock Is the Better Value Option?
Assertio (ASRT) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Assertio Holdings' (ASRT) second-quarter performance is likely to reflect the sales performance of its marketed drugs and cost savings from the company's restructuring plans.
Assertio (ASRT) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Assertio (ASRT) closed the most recent trading day at $3.11, moving +1.97% from the previous trading session.
Zacks.com featured highlights Assertio, Mercer International, and LGL
by Zacks Equity Research
Assertio, Mercer International, and LGL have been highlighted in this Screen of the Week article.
3 Best Breakout Stocks to Invest in for Attractive Returns
by Tirthankar Chakraborty
Assertio (ASRT), Mercer International (MERC) and The LGL Group (LGL) have been selected as the breakout stocks for today.
ASRT vs. ZTS: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
ASRT vs. ZTS: Which Stock Is the Better Value Option?
Assertio (ASRT) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Assertio (ASRT) closed the most recent trading day at $2.82, moving +0.71% from the previous trading session.
Centene (CNC) Divests Unit to Boost Focus on Core Business
by Zacks Equity Research
Centene (CNC) closes the deal to divest its pharmacy business. CNC primarily intends to pursue share repurchases with proceeds received from the transaction.
Here's Why Viracta Therapeutics (VIRX) is Up So Far This Year
by Zacks Equity Research
Viracta Therapeutics' (VIRX) Nana-val is being evaluated in multiple clinical studies in various subtypes of EBV-associated cancers.
Teladoc (TDOC) Widens Primary360 Offerings With New Services
by Zacks Equity Research
Teladoc (TDOC) will provide in-home and on-demand phlebotomy services for its Primary360 members with Scarlet Health's support.
Why You Should Hold Elevance Health (ELV) in Your Portfolio
by Zacks Equity Research
Elevance Health (ELV) continues witnessing a rise in the usage of its virtual care services, which is a vital driver.
Here's Why Assertio Holdings (ASRT) Stock is Up This Year
by Zacks Equity Research
Assertio Holdings' (ASRT) successful execution of its restructuring plan, resulting in significant cost savings, is boosting profits.
Zacks Industry Outlook Highlights Chinook Therapeutics, Assertio Holdings, Viracta Therapeutics and Soleno Therapeutics
by Zacks Equity Research
Chinook Therapeutics, Assertio Holdings, Viracta Therapeutics and Soleno Therapeutics are part of Zacks Industry Outlook article.
The Zacks Analyst Blog Highlights Assertio Holdings, Clipper Realty and Consolidated Water
by Zacks Equity Research
Assertio Holdings, Clipper Realty and Consolidated Water are part of Zacks top Analyst Blog.
Sysco and Etsy have been highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Sysco and Etsy are part of Zacks Bull and Bear of the Day article.
4 Small Stocks to Bet on in an Upbeat Drugs Industry
by Kinjel Shah
It is expected that innovation will continue to drive growth in the Medical-Drugs industry in 2022. KDNY, ASRT, VIRX, SLNO may prove to be good additions to one's portfolio.
The Zacks Analyst Blog Highlights Assertio Holdings, Brookfield Infrastructure, UnitedHealth and General Mills.
by Zacks Equity Research
Assertio Holdings, Brookfield Infrastructure, UnitedHealth and General Mills are part of Zacks top Analyst Blog.
3 Top Stocks That Stand to Gain From a Stronger Dollar
by Tirthankar Chakraborty
Stocks such as Assertio Holdings (ASRT), Clipper Realty (CLPR) and Consolidated Water (CWCO) should benefit as the dollar strengthens against its key counterparts.
Why Pediatrix Medical (MD) is a Solid Bet for Your Portfolio
by Zacks Equity Research
Pediatrix Medical (MD) is expected to boost its services across maternal-fetal medicine, neonatology and obstetrics, plus 18 pediatric subspecialty offerings.
Beat the Market Like Zacks: Assertio, Brookfield, UnitedHealth, General Mills in Focus
by Abhinab Dasgupta
Our time-tested methodologies were at work to help investors navigate the market well last week. Here are some of our accomplishments from last week.
Here's Why Select Medical (SEM) Stock is a Strong Buy Now
by Zacks Equity Research
Strategic alliances are bolstering Select Medical's (SEM) growth potential while mitigating the risk factor.
Factors that Make Molina Healthcare (MOH) an Attractive Bet Now
by Zacks Equity Research
Molina Healthcare (MOH) continues to ride on sustained top-line growth, well-performing Medicare and Medicaid businesses, and a strong cash position.
Is Assertio (ASRT) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Assertio (ASRT) and ProPhase Labs, Inc. (PRPH) have performed compared to their sector so far this year.
Universal Health (UHS) Cuts Guidance, Falls 6.1%: What's Ahead?
by Zacks Equity Research
Universal Health's (UHS) acute care hospitals experience lower-than-expected patient volumes in the second quarter, inducing a decline in revenues and profits.